Citation Impact
Citing Papers
Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997
2007
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
2010
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
2017 Standout
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
2012
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
2002 Standout
Circadian oscillation of nucleotide excision repair in mammalian brain
2009 StandoutNobel
Loss of cryptochrome reduces cancer risk in p53 mutant mice
2009 StandoutNobel
Cancer statistics, 2022
2022 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Cancer statistics, 2023
2023 Standout
Cancer statistics, 2020
2020 Standout
Cancer Statistics, 2021
2021 Standout
Recent advances in the management of AL Amyloidosis
2015
Dynamic PER repression mechanisms in the Drosophila circadian clock: from on-DNA to off-DNA
2010 StandoutNobel
PARMA international protocol: Pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)
1991
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis
2012
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
2002 Standout
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
1999 Standout
Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006
2010
Amyloid diseases of the heart: current and future therapies
2012
Cancer drug resistance: an evolving paradigm
2013 Standout
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia
2002
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
Regulation of nucleotide excision repair activity by transcriptional and post-transcriptional control of the XPA protein
2010 StandoutNobel
Coordinated Transcription of Key Pathways in the Mouse by the Circadian Clock
2002 Standout
Evaluating treatment strategies in chronic lymphocytic leukemia
2001
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
2013
Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction
2006 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Death receptors in chemotherapy and cancer
2004
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
2004
Chemotherapy and the war on cancer
2005 Standout
Four deaths and a funeral: from caspases to alternative mechanisms
2001 Standout
Circadian clock control of the cellular response to DNA damage
2010 StandoutNobel
Autologous bone marrow transplantation in adults with non‐Hodgkin's lymphoma: A southwest oncology group study
1994
Circadian rhythms and cancer chemotherapy
1995
Systemic amyloidosis
2015 Standout
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
2000
Sickle-cell disease
2010 Standout
Hematopoietic Stem-Cell Transplantation
2006 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy
2006
Secondary prevention with folic acid: effects on clinical outcomes
2003
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
2014
CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia
1999
Morning Hypertension: The Strongest Independent Risk Factor for Stroke in Elderly Hypertensive Patients
2006
Biochemical Analysis of the Canonical Model for the Mammalian Circadian Clock
2011 StandoutNobel
A clockwork web: circadian timing in brain and periphery, in health and disease
2003
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
2012
Histomorphometric effect of six month treatment with oral risedronate in patients with multiple myeloma
1993
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
2012
Mechanisms of Bone Metastasis
2004 Standout
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
2004
Biological Rhythms in the Physiology and Pharmacology of Blood Coagulation
1991
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Cancer of the Ovary
2004 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor
2006
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
2006
Mechanisms of Bone Lesions in Multiple Myeloma
1992
Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors
2002
Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia
2006
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
2011
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis
2007
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
2010
Current Trends in Diagnosis and Management of Cardiac Amyloidosis
2013
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
2011
A circadian gene expression atlas in mammals: Implications for biology and medicine
2014 Standout
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
2006 Standout
High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
1987
Circadian Rhythms: Mechanisms and Therapeutic Implications
2007
Toward the potential cure of leukemias in the next decade
2018
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Control of skin cancer by the circadian rhythm
2011 StandoutNobel
Regulation of apoptosis by the circadian clock through NF-κB signaling
2011 StandoutNobel
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
1999
Chimeric Antigen Receptor Therapy
2018 Standout
Circadian Variation in the Frequency of Onset of Acute Myocardial Infarction
1985
The Role of Clock Genes in Pharmacology
2010
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
2013
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
2005 Standout
Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL
2003
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
1999 Standout
PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues
2004 Standout
Circadian Clock, Cancer, and Chemotherapy
2014 StandoutNobel
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
2009
Health-Related Quality of Life in Younger Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study Group
2007
High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe
2005
Multiple Myeloma
2011 Standout
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease
2008
Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy
2005
Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials
1999
BCL2 translocations in leukemias of mature B cells
1994
Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia
2005
Parma international protocol: pilot study of DHAP followed by involved- field radiotherapy and BEAC with autologous bone marrow transplantation
1991
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
2012
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
2001
Works of J. Jaubert being referenced
Circadian changes in anticoagulant effect of heparin infused at a constant rate.
1985
Chlorambucil in Indolent Chronic Lymphocytic Leukemia
1998
t(2; 18) and t(18;22) Variant Chromosomal Translocations in B Cell Malignancies
1992
Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: Preliminary results of an open French multicentre randomized study
1991
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
2001
Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95
2010
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
2007
Expression and prognostic significance of Bcl‐2 family proteins in myelodysplastic syndromes
2002
Histologic evidence of an abnormal bone remodeling in b-cell malignancies other than multiple myeloma
1988
Massive therapy and autologous bone marrow transplantation in pediatric and young adults Burkitt's lymphoma (30 courses on 28 patients: a 5-year experience)
1986
[Biological rhythm and thromboembolic disease. Physiological, epidemiological and pharmacological aspects].
1987
Chromosome studies in stimulated lymphocytes of 50 patients with B-cell chronic lymphocytic leukemia.
1992
Randomized Clinical Trial Comparing Melphalan-Prednisone (MP), MP-Thalidomide (MP-THAL) and High-Dose Therapy Using Melphalan 100 MG/M2 (MEL100) for Newly Diagnosed Myeloma Patients Aged 65–75 Years. Interim Analysis of the IFM 99-06 Trial on 350 Patients.
2004
Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients with AL (Primary) Amyloidosis: Results of the French Multicentric Randomized Trial (MAG and IFM Intergroup).
2005